Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Depreciation & Amortization (CF) (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Depreciation & Amortization (CF) for 13 consecutive years, with $139000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 7.95% to $139000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $612000.0, a 7.69% decrease, with the full-year FY2025 number at $612000.0, down 7.69% from a year prior.
  • Depreciation & Amortization (CF) was $139000.0 for Q4 2025 at Niagen Bioscience, down from $157000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $235000.0 in Q3 2022 to a low of $139000.0 in Q4 2025.
  • A 5-year average of $195200.0 and a median of $206000.0 in 2021 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): rose 13.43% in 2023, then decreased 29.61% in 2024.
  • Niagen Bioscience's Depreciation & Amortization (CF) stood at $211000.0 in 2021, then grew by 4.74% to $221000.0 in 2022, then decreased by 19.91% to $177000.0 in 2023, then decreased by 14.69% to $151000.0 in 2024, then dropped by 7.95% to $139000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Depreciation & Amortization (CF) are $139000.0 (Q4 2025), $157000.0 (Q3 2025), and $158000.0 (Q2 2025).